

Paul Cusenza has joined Perlegen Sciences (Mountain View, CA) as vice president of alliance management, a newly created role. Mr. Cusenza was formerly managing director of value added alliances and vice president, marketing & analysis at Capital One Financial. Most recently, he has been an independent consultant and assisted Perlegen prior to its spin-off from Affymetrix.

GenVec (Gaithersburg, MD) has announced the election of the Honorable **Barbara Hackman Franklin** to its board of directors. Ms. Franklin is president and CEO of Barbara Franklin Enterprises, a private consulting and investment firm, and previously served as the 29th United States Secretary of Commerce in the administration of George H. W. Bush. She is a member of the boards of Aetna, The Dow Chemical Company, MedImmune, Milacron, and Watson Wyatt & Co.

Neose Technologies (Horsham, PA) has announced the appointment of **L. Patrick Gage** to its board of directors. Dr. Gage recently retired from his positions as senior vice president, science and technology at Wyeth and president of Wyeth Research. Previously, he served in several capacities, including president, at Genetics Institute.

Onyx Pharmaceuticals (Richmond, CA) has announced the election of **Antonio J. Grillo-Lopez** to the company's board of directors. Dr. Grillo-Lopez retired from IDEC Pharmaceuticals in 2001 and was named chief medical officer emeritus. He also serves as chairman of the Neoplastic and Autoimmune Disease Research Institute, consultant in clinical research and regulatory strategy to the National Cancer Institute, and on the boards of Tragen Pharmaceuticals, Conforma Therapeutics, Salmedix, SuperGen, the Lymphoma Research Foundation, and The National Coalition for Cancer Survivorship.

BioStratum (Research Triangle Park, NC) has appointed chief executive officer **Claus Kuhl** to the additional post of vice chairman of the board of directors. The company has also announced the promotions of **Robert J. Schotzinger**, previously chief medical officer, to president and chief operating officer, and **Gary M. Gordon**, previously vice president of business development, to vice president of finance and business development and chief financial officer.

François Pons has been named director of business development at Genome Express (Grenoble, France). Mr. Pons joins the company from the Centre d'Immunologie Pierre Fabre, where he was most recently director of business development and scientific com-

munication, and prior to that served in strategic marketing positions at Baxter Healthcare France.

George Poste has been named to the position of chairman of Orchid BioSciences (Princeton, NJ), replacing **Dale R. Pfost**, who remains as Orchid's president and CEO. Dr. Poste is the former president of R&D and chief science and technology officer at SmithKline Beecham, and current CEO of Health Technology Networks. He has been a member of Orchid's board of directors since April 2000. In addition, **Andrew P. Savadelis** has been appointed chief financial officer and senior vice president of finance at Orchid. Most recently, Mr. Savadelis was principal at Stratus Photonics. He fills the position previously held by **Donald R. Marvin**, who has served in the dual roles of CFO for Orchid BioSciences and as general manager of Orchid Diagnostics. Mr. Marvin will continue as head of Orchid Diagnostics.

Entelos (Menlo park, CA) has announced the appointment of **Jon S. Saxe** as chairman of the board. From January 1995 to May 1999, Mr. Saxe was president of Protein Design Labs, where he continues to serve as a director and member of the executive committee. He is also an executive-in-residence at Institutional Venture Partners, as well as a director at RiboGene, Incyte Genomics, ID Biomedical, and POINT Biomedical.

Tony Sedgwick has been named chief executive officer of Cambridge Biotechnology (Cambridge, UK). He joins the company from Roche, where he was global head of clinical operations and a member of the global development management team.

Millennium Pharmaceuticals (Cambridge, MA) has appointed **Shelley Spencer** to the position of general manager, metabolic diseases. She joins Millennium after a 15-year career at Bristol-Myers Squibb, culminating in her position as vice president, global marketing, metabolics.

Duncan H. Walker has been appointed vice president, discovery biology for Sunesis Pharmaceuticals (S. San Francisco, CA). He joins the company from Hoffmann-La Roche, where most recently he held the position of vice president, oncology. In addition, Sunesis announced that **Robert McDowell** has been promoted to vice president, discovery chemistry, replacing **Eric Gordon**, who recently announced his retirement after 30 years in the pharmaceutical industry. Prior to joining Sunesis in 2000, Dr. McDowell served as director of structural chemistry at Axys Pharmaceuticals (now Celera Genomics).